Lilly outlines $1bn India manufacturing expansion
The investment will cover CMO collaborations and a new manufacturing and quality hub in Hyderabad.
List view / Grid view
The investment will cover CMO collaborations and a new manufacturing and quality hub in Hyderabad.
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
The deal with the US biopharma adds a portfolio of clinical-stage incretin and amylin research programmes to its pipeline.
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
Biotech and research investments from Lilly and AstraZeneca also put on hold as pricing row rumbles on.
And Eli Lilly and Company’s new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials.
Her leadership experience spans three decades with Lilly, across multiple therapeutic areas including oncology, neuroscience and infectious disease.
Disruption to traditional distribution channels is anticipated to hinder widespread adoption of the channel.
The pharma company’s digital innovation efforts also progress with the opening of a new Hyderabad facility.
The new findings support a limited duration dosing approach and highlight the consistent safety profile for Eli Lilly’s antibody drug.
Upcoming drug approvals and clinical progress will be pivotal during the third quarter of the year, says GlobalData.
The agreement between Eli Lilly and Company and Verve Therapeutics could lead the way to single treatments that provide a long-term reduction of cardiovascular risk factors.
Advanced technology innovation is driving lower R&D costs and progress of targeted treatments such as cell and gene therapies, the research reports.
The deal will support Eli Lilly and Company to advance non-opioid medicines and expand its pain therapy pipeline.